Our long-term research goal is to unravel the molecular mechanisms underlying cellular signaling and leverage this knowledge to develop novel therapeutic strategies. Specifically, we focus on oncogenic signaling pathways to identify key molecular targets and explore potential combination therapies for aggressive B-cell lymphomas. By integrating multidisciplinary approaches, including molecular biology, biochemistry, and advanced genomics, we aim to uncover new therapeutic vulnerabilities and improve treatment outcomes for patients with these challenging lymphoid malignancies.